384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study

Alés-Martínez, J E; Morales, S; Fernández Abad, M; Sánchez-Rovira, P; Salvador Bofill, F J; Lahuerta, A; García-Sáenz, J A; Garau Llinas, I; Díaz Redondo, T; Ferrer, N; Carañana, V; López, R; Alonso Soler, S E; Bermejo, B; de la Haba, J; Zamora, P; Balmana, J; López-Miranda, E; Cortés, J; Llombart Cussac, A

期刊名称Annals of Oncology
作者Alés-Martínez, J E; Morales, S; Fernández Abad, M; Sánchez-Rovira, P; Salvador Bofill, F J; Lahuerta, A; García-Sáenz, J A; Garau Llinas, I; Díaz Redondo, T; Ferrer, N; Carañana, V; López, R; Alonso Soler, S E; Bermejo, B; de la Haba, J; Zamora, P; Balmana, J; López-Miranda, E; Cortés, J; Llombart Cussac, A
卷第30卷
印刷ISSN0923-7534
电子ISSN1569-8041
文件大小99.07KB
发表时间2019-10-01
DOI10.1093/annonc/mdz242.079

发现好书期刊，享受阅读乐趣

384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study